GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Intersect ENT Inc (NAS:XENT) » Definitions » Beneish M-Score

Intersect ENT (Intersect ENT) Beneish M-Score : -3.96 (As of May. 12, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Intersect ENT Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.96 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Intersect ENT's Beneish M-Score or its related term are showing as below:

XENT' s Beneish M-Score Range Over the Past 10 Years
Min: -4.82   Med: -2.45   Max: 55.26
Current: -3.96

During the past 10 years, the highest Beneish M-Score of Intersect ENT was 55.26. The lowest was -4.82. And the median was -2.45.


Intersect ENT Beneish M-Score Historical Data

The historical data trend for Intersect ENT's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intersect ENT Beneish M-Score Chart

Intersect ENT Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.60 -2.66 -3.02 36.40 -3.71

Intersect ENT Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.38 55.26 44.17 -3.71 -3.96

Competitive Comparison of Intersect ENT's Beneish M-Score

For the Medical Devices subindustry, Intersect ENT's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intersect ENT's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Intersect ENT's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Intersect ENT's Beneish M-Score falls into.



Intersect ENT Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Intersect ENT for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7424+0.528 * 0.8621+0.404 * 0.376+0.892 * 1.2227+0.115 * 0.8401
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9937+4.679 * -0.11408-0.327 * 2.7247
=-3.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar22) TTM:Last Year (Mar21) TTM:
Total Receivables was $13.2 Mil.
Revenue was 21.575 + 30.671 + 24.4 + 27.349 = $104.0 Mil.
Gross Profit was 13.885 + 22.533 + 19.313 + 19.017 = $74.7 Mil.
Total Current Assets was $87.5 Mil.
Total Assets was $127.4 Mil.
Property, Plant and Equipment(Net PPE) was $20.3 Mil.
Depreciation, Depletion and Amortization(DDA) was $4.0 Mil.
Selling, General, & Admin. Expense(SGA) was $122.0 Mil.
Total Current Liabilities was $46.4 Mil.
Long-Term Debt & Capital Lease Obligation was $157.6 Mil.
Net Income was -28.804 + -91.154 + -31.849 + -16.601 = $-168.4 Mil.
Non Operating Income was -3.212 + -67.896 + -13.654 + 0.442 = $-84.3 Mil.
Cash Flow from Operations was -26.86 + -15.713 + -13.366 + -13.616 = $-69.6 Mil.
Total Receivables was $14.6 Mil.
Revenue was 24.328 + 28.228 + 22.72 + 9.78 = $85.1 Mil.
Gross Profit was 15.873 + 19.534 + 14.875 + 2.423 = $52.7 Mil.
Total Current Assets was $102.3 Mil.
Total Assets was $210.4 Mil.
Property, Plant and Equipment(Net PPE) was $22.1 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.5 Mil.
Selling, General, & Admin. Expense(SGA) was $100.4 Mil.
Total Current Liabilities was $43.5 Mil.
Long-Term Debt & Capital Lease Obligation was $80.1 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(13.236 / 103.995) / (14.581 / 85.056)
=0.127275 / 0.171428
=0.7424

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(52.705 / 85.056) / (74.748 / 103.995)
=0.619651 / 0.718765
=0.8621

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (87.477 + 20.321) / 127.393) / (1 - (102.287 + 22.055) / 210.439)
=0.153815 / 0.40913
=0.376

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=103.995 / 85.056
=1.2227

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(3.547 / (3.547 + 22.055)) / (4.013 / (4.013 + 20.321))
=0.138544 / 0.164913
=0.8401

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(122.019 / 103.995) / (100.427 / 85.056)
=1.173316 / 1.180716
=0.9937

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((157.571 + 46.413) / 127.393) / ((80.129 + 43.538) / 210.439)
=1.601218 / 0.587662
=2.7247

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-168.408 - -84.32 - -69.555) / 127.393
=-0.11408

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Intersect ENT has a M-score of -3.96 suggests that the company is unlikely to be a manipulator.


Intersect ENT Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Intersect ENT's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Intersect ENT (Intersect ENT) Business Description

Traded in Other Exchanges
N/A
Address
1555 Adams Drive, Menlo Park, CA, USA, 94025
Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer's PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.
Executives
Elisabeth Sandoval director C/O KYTHERA BIOPHARMACEUTICALS, INC., 30930 RUSSELL RANCH ROAD, 3RD FLOOR, WESTLAKE VILLAGE CA 91362
Neil A Hattangadi director 1555 ADAMS DRIVE MENLO PARK CA 94025
Reyna M Fernandez officer: Chief Human Resource Officer C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Patrick A Broderick officer: EVP, GC & Corporate Secretary C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Thomas A. West director, officer: President and CEO C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Richard A Meier officer: EVP & Chief Financial Officer C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Binney Robert H Jr officer: Vice President, Sales 1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Susan P Stimson officer: Vice President, Marketing 1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Lisa D Earnhardt director, officer: See Remarks 1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
David Aaron Lehman officer: General Counsel C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Jeryl L Hilleman officer: Chief Financial Officer C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Christine R Kowalski officer: Chief Operations Officer C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025
Mead Dana G Jr. director 2750 SAND HILL ROAD, MENLO PARK CA 94025
Richard E Kaufman officer: See Remarks 1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Gwen R. Carscadden officer: Chief People Officer C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025

Intersect ENT (Intersect ENT) Headlines

From GuruFocus

Intersect ENT to Report First Quarter 2021 Financial Results

By Business Wire Business Wire 04-20-2021

Intersect ENT Announces New Appointments to Executive Leadership Team

By Business Wire Business Wire 11-18-2020